Ferring Hails World First Positive Phase III Data For Microbiome Product

US Filing Planned For Later This Year

Preliminary efficacy findings from an ongoing pivotal study of Ferring's RBX2660 showed that the first-in-class microbiota-based therapy helped restore the gut microbiome and break the cycle of recurrence of C diff. infection.

Leading
Ferring Out In Front In The Microbiome Field • Source: Shutterstock

It has been a long wait but Ferring Pharmaceuticals AS has reported the world’s first positive Phase III results for any microbiome-based therapy with its non-antibiotic RBX2660 closing in on a filing for reducing recurrent Clostridioides difficile (C diff) infection in adults.

The Swiss firm's Rebiotix Inc. subsidiary has announced preliminary positive efficacy findings from an ongoing pivotal study of RBX2660...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas